Halaven eribulin mesylate regulatory update

Eisai said the Centers for Medicare & Medicaid Services (CMS) issued a permanent J-code for reimbursement of Eisai's breast cancer drug Halaven eribulin mesylate. J9179, the code for Halaven, became e...